| Age, y . | Min 17, max 75, median 52.5, mean 49.34 . |
|---|---|
| Sex | Female n = 6, male n = 23 |
| Diagnosis at inclusion | Anaplastic astrocytoma n = 5 (17.2%), anaplastic oligodendroglioma n = 4 (13.8%), glioblastoma n = 22 (75.9%) |
| Epilepsy during follow-up | n = 14 (48%) |
| Motor deficit at diagnosis | n = 8 (27.5%) |
| Maximal size in T1 + Gd at diagnosis, mm | Min 0, max 80.6, mean 41.03, median 40 |
| Maximal size in T2 at diagnosis, mm | Min 20.7, max 126, mean 67.9, median 70 |
| Location | Frontal n = 12 (41.3%), temporal n = 8 (27.5%), temporoparietal n = 2 (6.8%), occipital n = 1 (3.4%), central n = 4 (13.8%), insular n = 2 (6.8%) |
| Ki67 (%) | Min 3, max 70, mean 24.8, median 20 |
| MGMT promoter methylation | n = 16 (55%) |
| IDH-1 mutation | Negative n = 15 (51.7%), positive n = 9 (31%), unknown n = 3 (10.3%) |
| Operative complications | 1 meningitis, 2 intratumoral bleedings |
| Age, y . | Min 17, max 75, median 52.5, mean 49.34 . |
|---|---|
| Sex | Female n = 6, male n = 23 |
| Diagnosis at inclusion | Anaplastic astrocytoma n = 5 (17.2%), anaplastic oligodendroglioma n = 4 (13.8%), glioblastoma n = 22 (75.9%) |
| Epilepsy during follow-up | n = 14 (48%) |
| Motor deficit at diagnosis | n = 8 (27.5%) |
| Maximal size in T1 + Gd at diagnosis, mm | Min 0, max 80.6, mean 41.03, median 40 |
| Maximal size in T2 at diagnosis, mm | Min 20.7, max 126, mean 67.9, median 70 |
| Location | Frontal n = 12 (41.3%), temporal n = 8 (27.5%), temporoparietal n = 2 (6.8%), occipital n = 1 (3.4%), central n = 4 (13.8%), insular n = 2 (6.8%) |
| Ki67 (%) | Min 3, max 70, mean 24.8, median 20 |
| MGMT promoter methylation | n = 16 (55%) |
| IDH-1 mutation | Negative n = 15 (51.7%), positive n = 9 (31%), unknown n = 3 (10.3%) |
| Operative complications | 1 meningitis, 2 intratumoral bleedings |
Abbreviations: Gd, gadolinium; IDH-1, isocitrate dehydrogenase 1; max, maximum; MGMT, O6-methylguanine–DNA methyltransferase; Min, minimum.
| Age, y . | Min 17, max 75, median 52.5, mean 49.34 . |
|---|---|
| Sex | Female n = 6, male n = 23 |
| Diagnosis at inclusion | Anaplastic astrocytoma n = 5 (17.2%), anaplastic oligodendroglioma n = 4 (13.8%), glioblastoma n = 22 (75.9%) |
| Epilepsy during follow-up | n = 14 (48%) |
| Motor deficit at diagnosis | n = 8 (27.5%) |
| Maximal size in T1 + Gd at diagnosis, mm | Min 0, max 80.6, mean 41.03, median 40 |
| Maximal size in T2 at diagnosis, mm | Min 20.7, max 126, mean 67.9, median 70 |
| Location | Frontal n = 12 (41.3%), temporal n = 8 (27.5%), temporoparietal n = 2 (6.8%), occipital n = 1 (3.4%), central n = 4 (13.8%), insular n = 2 (6.8%) |
| Ki67 (%) | Min 3, max 70, mean 24.8, median 20 |
| MGMT promoter methylation | n = 16 (55%) |
| IDH-1 mutation | Negative n = 15 (51.7%), positive n = 9 (31%), unknown n = 3 (10.3%) |
| Operative complications | 1 meningitis, 2 intratumoral bleedings |
| Age, y . | Min 17, max 75, median 52.5, mean 49.34 . |
|---|---|
| Sex | Female n = 6, male n = 23 |
| Diagnosis at inclusion | Anaplastic astrocytoma n = 5 (17.2%), anaplastic oligodendroglioma n = 4 (13.8%), glioblastoma n = 22 (75.9%) |
| Epilepsy during follow-up | n = 14 (48%) |
| Motor deficit at diagnosis | n = 8 (27.5%) |
| Maximal size in T1 + Gd at diagnosis, mm | Min 0, max 80.6, mean 41.03, median 40 |
| Maximal size in T2 at diagnosis, mm | Min 20.7, max 126, mean 67.9, median 70 |
| Location | Frontal n = 12 (41.3%), temporal n = 8 (27.5%), temporoparietal n = 2 (6.8%), occipital n = 1 (3.4%), central n = 4 (13.8%), insular n = 2 (6.8%) |
| Ki67 (%) | Min 3, max 70, mean 24.8, median 20 |
| MGMT promoter methylation | n = 16 (55%) |
| IDH-1 mutation | Negative n = 15 (51.7%), positive n = 9 (31%), unknown n = 3 (10.3%) |
| Operative complications | 1 meningitis, 2 intratumoral bleedings |
Abbreviations: Gd, gadolinium; IDH-1, isocitrate dehydrogenase 1; max, maximum; MGMT, O6-methylguanine–DNA methyltransferase; Min, minimum.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
